Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 14 Urinary Bladder Neoplasms 13 Colorectal Neoplasms 10 Carcinoma, Merkel Cell 9 Breast Neoplasms 9 Carcinoma, Renal Cell 7 Neoplasms 6 Neoplasm Metastasis 6 Carcinoma, Non-Small-Cell Lung 6 Small Cell Lung Carcinoma 4 Carcinoma, Hepatocellular 4 Turcot syndrome 3 Stomach Neoplasms 3 Neuroendocrine Tumors 3 Head and Neck Neoplasms 3 Endometrial Neoplasms 3 Urethral Neoplasms 2 Ureteral Neoplasms 2 Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Penile Neoplasms 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Melanoma 2 Lung Neoplasms 2 Glioblastoma 2 Gastrointestinal Neoplasms 2 Colonic Neoplasms 2 Carcinoma, Squamous Cell 2 Carcinoma, Neuroendocrine 2 Uterine Cervical Neoplasms 1

Interventions

enfortumab vedotin 2 Gemcitabine 2 Carboplatin 2 zimberelimab 1 sacituzumab govitecan 1 pembrolizumab 1 olaparib 1 avelumab 1 Oxaliplatin 1 Nivolumab 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Metastatic Urothelial Cancer × avelumab × Clear all

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡